ArticleThe World Allergy Organization journal2026
Sleep quality, disturbance and the prevalence of obstructive sleep apnoea in chronic spontaneous urticaria and associated risk factors.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic spontaneous urticaria (CSU) is a common dermatological disorder impairing quality of life. The impact of CSU on sleep quality and obstructive sleep apnoea remains unclear. Objective: To estimate the prevalence of sleep disturbance and obstructive sleep apnoea (OSA) in CSU patients and identify associated risk factors. Methods: We conducted an analytical cross-sectional study involving adult CSU patients (n = 327) per eligibility criteria. We used the Pittsburgh Sleep Quality Index (PSQI) and STOP-Bang questionnaires to evaluate sleep disturbance and risk for OSA, respectively. Furthermore, we evaluated disease characteristics, including urticaria control and laboratory parameters, and assessed their association with sleep disturbance and risk for OSA. Results: Poor sleep quality was reported by 59.3% CSU patients, while 61.5% presented with intermediate-to-high risk for OSA. PSQI score showed a positive correlation with mean platelet volume (p = 0.03), and negative correlations with age (p = 0.01), BMI (p = 0.04) and the Urticaria Control Test (UCT) score (p = 0.01). The STOP-Bang score showed a positive correlation with age (p < 0.001), BMI (p < 0.001), UCT score (p = 0.008) and PLR (p < 0.001), while the absolute eosinophil count was negatively correlated (p = 0.0006). Symptomatic dermographism (OR 2.4) significantly increased the odds of poor sleep, while uncontrolled urticaria (OR 0.5) and dyslipidemia (OR 0.4) reduced its odds. Female gender (OR 12.3), uncontrolled urticaria (OR 2.7) and dyslipidaemia (OR 3.1) were significant positive predictors for moderate-to-severe risk for OSA. Conclusion: CSU patients frequently experience disturbed sleep and are at risk for developing OSA. Awareness about these comorbidities is important to enable their early identification and appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.